17 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark Office (USPTO) has completed its examination of patent application 15/613,030, entitled: “Low oxygen culture conditions for maintaining retinal progenitor cell multipotency”, and has issued a notification of allowance for the issuance of a patent.